Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Banyu develops factor Xa inhibitors as antiplatelet/antithrombotic agents

April 2, 1998

Preliminary results of TIMI 15A trial reported at ACC

April 1, 1998

Anticoagulants in development at DuPont Merck

April 1, 1998

Potent and selective PDE III inhibitor in development at Otsuka

March 31, 1998

New antiplatelet and antithrombotic agent characterized by Taisho

March 31, 1998

Toyama researchers characterize antiplatelet/antithrombotic effects of T-250

March 31, 1998

Platelet antiaggregatory effects of liposome-encapsulated streptokinase

March 30, 1998

Z-335 demonstrates beneficial effects in models of peripheral circulatory insufficiency

March 30, 1998

DuPont Merck obtains U.S. rights for anticoagulant

March 27, 1998

Selective factor Xa inhibitors in development at Banyu

March 25, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 25, 2025.
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 24, 2025
Clots and metastasis in cancer patients start in the lung
BioWorld MedTech
The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by Cornell University scientists. In the...
Roche looks to grow with sequencing by expansion tech
BioWorld MedTech
Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...